Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: Data from the UK Juvenile-onset systemic lupus erythematosus cohort study

Teresa Giani1,2, Eve MD Smith3,4, Eslam Al-Abadi5, Kate Armon6, Kathryn Bailey7, Coziana Ciurtin8, Joyce Davidson9, Janet Gardner-Medwin10, Kirsty Haslam11, Dan P Hawley12, Alice Leahy13, Valentina Leone14, Flora McErlane15, Devesh Mewar16, Gita Modgil17, Robert Moots18, Clarissa Pilkington19, Francesca Pregniolato20, Athimalaipet V Ramanan21, Satyapal Rangaraj22, Phil Riley23, Arani Sridhar24, Nick Wilkinson25, Rolando Cimaz26,27, Michael W Beresford3,4, Christian M Hedrich3,4, and on behalf of the UK JSLE Cohort Study

Abstract

Introduction: Juvenile-onset systemic lupus erythematosus (JSLE) is a rare autoimmune/inflammatory disease with significant morbidity and mortality. Neuropsychiatric (NP) involvement is a severe complication, encompassing a heterogeneous range of neurological and psychiatric manifestations.

Methods: Demographic, clinical, and laboratory features of NP-SLE were assessed in participants of the UK JSLE Cohort Study, and compared to patients in the same cohort without NP manifestations.

Results: A total of 428 JSLE patients were included in this study, 25% of which exhibited NP features, half of them at first visit. Most common neurological symptoms among NP-JSLE patients included headaches (78.5%), mood disorders (48.6%), cognitive impairment (42%), anxiety (23.3%), seizures (19.6%), movement disorders (17.7%), and cerebrovascular disease (14.9%). Peripheral nervous system involvement was recorded in 7% of NP-SLE patients. NP-JSLE patients more frequently exhibited thrombocytopenia (<100 × 10^9/L) \((p = 0.04)\), higher C-reactive protein levels \((p = 0.01)\), higher global pBILAG score at first visit \((p < 0.001)\), and higher SLICC damage index score at first \((p = 0.02)\) and last \((p < 0.001)\) visit when compared to JSLE patients without NP involvement.

Conclusions: A significant proportion of JSLE patients experience NP involvement (25%). Juvenile-onset NP-SLE most commonly affects the CNS and is associated with increased overall disease activity and damage.

Keywords
Systemic lupus erythematosus, neuropsychiatric, central nervous system, peripheral nervous system, pediatric, juvenile

Date received: 29 March 2020; accepted: 19 August 2021

Introduction

Systemic lupus erythematosus (SLE) is a severe and potentially life-threatening chronic autoimmune/inflammatory disease that can affect any organ system. The molecular pathophysiology of SLE is complex and incompletely understood. While relatively few SLE patients experience “purely” genetic forms that are caused by mutations in single genes, most individuals exhibit genetic predispositions in the context of environmental and hormonal factors. The key contribution of genetic factors is underscored by highly variable incidences between ethnicities. The highest incidence and prevalence of SLE worldwide have been reported in North America \([23.2/100 000\text{ person-years (95\% CI: 23.4–24.0)}\text{ and 241/100 000 people (95\% CI: 130–352), respectively}]\), while lowest incidences were
Approximately 15–20% of SLE patients develop disease before their 16th birthday and are diagnosed with juvenile-onset systemic lupus erythematosus (JSLE). Disease onset in childhood and adolescence is associated with more severe disease presentations, increased organ damage (already at the time of diagnosis), and an even more variable clinical and serological picture when compared to the adult age group.

Neuropsychiatric (NP) involvement is a potentially severe complication that can increase disease burden, and cause significant damage and disability. The variable presentation of NP disease is reflected by the presence of 19 items in the American College of Rheumatology (ACR) classification for NP-SLE, including items related to both the central (CNS) and/or peripheral (PNS) nervous system. Though based on a limited number of reports, NP-SLE appears to be more common and aggressive among children and adolescents as compared to patients with adult-onset SLE. As many as 22–95% of JSLE patients develop NP disease, while 14–80% of adult-onset SLE patients are affected. To date, few comparative studies have analyzed NP involvement in children and adults. Reports underscore that neurologic manifestations are not uncommon in JSLE, contributing to the increased morbidity and mortality demonstrated in the pediatric age group.

Thus, timely diagnosis, and treatment of NP-SLE is critical to improve patients’ quality of life and prevent damage. This study aimed to investigate the prevalence, demographic characteristics, and clinical features of NP disease in JSLE patients enrolled in the UK JSLE Cohort Study. Furthermore, associations between NP involvement and other clinical and/or laboratory features, as well correlation with disease severity and outcomes were investigated.

Materials and Methods

Study Cohort

This study was based upon the UK JSLE Cohort, a multidisciplinary, multicenter collaborative network established in 2006 with the primary aim of determining the clinical characteristics of JSLE patients across the UK, as well as supporting a program of clinical translational research (for details, see http://www.liv.ac.uk/ukjsle). The Study collects detailed data on demographics, ACR criteria for the classification of SLE, disease activity, medication use, and disease damage scores on a regular basis (see below). The UK JSLE Cohort is managed by the national coordinating center in Liverpool (CI: Beresford), with participating institutions including the majority of pediatric rheumatology/nephrology centers in the UK (n = 23). The JSLE Cohort Study has full ethical approvals in place (National Research Ethics Service North West, Liverpool, UK, reference 06/Q1502/77), and patient/parental consent or assent to take part in the study was obtained from all families. The research was carried out in accordance with the Declaration of Helsinki.
Patients. All JSLE patients were followed between August 2006 and August 2019. Patients were aged ≤16 years at the time of diagnosis and satisfied ≥4 ACR classification criteria for SLE. Patients with NP manifestations preceding the diagnosis of JSLE by more than 6 months were not included in the analysis. Patients with isolated headaches, mood or anxiety disorders as the only neurological manifestation were excluded from the group of NP-JSLE patients, as these symptoms are relatively prevalent in the general population, and therefore may be unrelated to JSLE. However, the importance of these symptoms was considered within the “no NP involvement” sub-cohort of the study.

Data collected. Demographic (gender, age at diagnosis, ethnicity, and family history for autoimmune disease), clinical and laboratory information (ACR-1997 classification criteria for SLE, the Systemic Lupus International Collaborating Clinic Damage Index (SLICC-SDI) \(^\text{18,19}\), the pediatric version of British Isles Lupus Assessment Group (BILAG; pBILAG2004) disease activity score, \(^\text{18}\) laboratory values including autoantibody status of JSLE patients enrolled in the UK JSLE Cohort Study were included in this study. One hundred and seven (25%) developed NP features, with onset early in the disease (already present at first visit) in 52/107 (48.5%) of them. The mean follow-up period was 4.8 years (range: 0.2–15.4) for the entire cohort, and 5.6 years (range: 0.2–14.4) for patients with NP involvement \((p = 0.04)\). Demographic information and family history of the study population are summarized in Table 1. No significant differences emerged in relation to age at disease onset and/or diagnosis, ethnicity, gender, and family history for autoimmune diseases when comparing subjects with and without NP involvement.

Clinical characteristics of NP-SLE

The majority of NP manifestations (92.7%) were related to involvement of the CNS, as opposed to the PNS (Figure 1). Even after the exclusion of isolated headaches (see Materials & Methods), headaches were the most frequently observed potential symptom of NP-SLE, observed in 84/107 (78.5%) patients. Tension headaches represented 75% of all headache types (63/84 of patients), followed by episodic headaches (38/84 patients), “severe” headaches (23.8%, 20/84 patients), cluster headaches (3.5%, 3/84 patients), and hypertension-related headaches (1.2%, 1/84 patient). Fifty-four patients (64%) experienced more than one type of headache. Among the 321 JSLE patients with “no NP involvement” sub-cohort, headaches were reported by 177/321 (55.1%), with tension headaches being the most common (55%), while “severe” headaches were reported by 5% of these, and 16/177 (9%) experience at least of two different co-existing types of headaches.

Mood disorder was the second most common NP manifestation, documented in 52/107 (48.6%) NP-SLE patients (9 of whom had major depression), followed by cognitive dysfunction (45/107, 42%), anxiety disorder (25/107, 23.3%), seizures (21/107, 19.6%), movement disorders (19/107, 17.7%), cerebrovascular disease (16/107, 14.9%), mononeuropathy (9/107, 8.4%) acute confusional state (7/107, 6.5%), psychosis (10/107, 9.3%), and cranial neuropathy (6/107, 5.6%). Table 2 summarizes the prevalence of each NP manifestation in the studied cohort, also offering a comparison with comparable pediatric series published within the last 15 years.

Seventeen of 107 NP-SLE patients (15.8%) experienced one neurological manifestation (other than isolated headaches, mood disorder, and/or anxiety), while 15/107 (14%) experienced two, 25/107 (23.3%) experienced three, 21/107 (19.6%) experienced four; and the remaining 29/107 subjects (27%) had five or more concurrent NP manifestations. There were no significant differences in the presence of NP

Results

Patient demographics

A total of 428 JSLE patients recruited to the UK JSLE Cohort Study were included in this study. One hundred and seven (25%) developed NP features, with onset early in the disease (already present at first visit) in 52/107 (48.5%) of them. The mean follow-up period was 4.8 years (range: 0.2–15.4) for the entire cohort, and 5.6 years (range: 0.2–14.4) for patients with NP involvement \((p = 0.04)\). Demographic information and family history of the study population are summarized in Table 1. No significant differences emerged in relation to age at disease onset and/or diagnosis, ethnicity, gender, and family history for autoimmune diseases when comparing subjects with and without NP involvement.

Statistical analysis. For comparative analyses, patients were grouped on the basis of SLE in the presence or absence of NP involvement. Furthermore, JSLE patients with NP involvement were subgrouped into “early” appearance of NP symptoms, if present already at first visit, or “late” NP involvement if it developed later, and was registered at last visit. Lupus-related variables that were assessed included the number of ACR classification criteria present at first and last visit, \(^\text{17}\) the pBILAG2004 disease activity scores at first and last visit, \(^\text{18}\) and the SLICC-SDI at first and last visit. \(^\text{18,19}\) “Severe” NP involvement was defined by a pBILAG score of A in the NP domain, “moderate” NP involvement as a B, “mild” NP involvement as C; NP pBILAG scores of D reflect a history of NP involvement and current inactivity, E the absence of NP involvement.

Descriptive statistical analysis (mean, SD) was performed using Microsoft Excel 2016. Comparison between groups was performed using Mann–Whitney U or Chi-square tests, as appropriate (Minitab19.2020.1; Graph-PadPrism 6.0). Due to the exploratory nature of the analysis, adjustments for multiple comparisons were not made. Statistical significance was assumed at \(p < 0.05\).
Figure 1. Frequency of neuropsychiatric syndromes. Distribution of each neuropsychiatric syndrome in the present series among the 19 standardized neuropsychiatric syndromes linked to systemic lupus erythematosus identified by the American College of Rheumatology ad hoc Committee.8 Peripheral, neuropsychiatric feature involving the peripheral nervous system. “Others” include: acute confusional state, aseptic meningitis, Guillain Barré syndrome, and myelopathy that individually represent less than 2.5% of all manifestations.
events based on age at diagnosis (mean age 12.2 years for patients without NP involvement vs 11.5 years in patients with NP involvement, \( p = 0.05 \)).

**Laboratory features associated with NP-JSLE**

Between JSLE patients with versus without NP involvement, no statistically significant differences were seen in relation to autoantibody positivity (ANA, Anti-Sm, anti-dsDNA, anti-SS-A/Ro and SS-B/La, anti-phospholipid), white blood cell counts (total, neutrophils, lymphocytes), erythrocyte sedimentation rate (ESR), and levels of hemoglobin, serum creatinine, thyroid-stimulating hormone, thyroxine, total-, LDL-, and HDL-cholesterol.

Significantly reduced platelet counts (<100 x 10^9/L) were observed at first visit in patients with NP involvement (\( p = 0.04 \)); serum C-reactive protein (CRP) levels were higher in patients with NP involvement (mean: 28.2 mg/L in children with NP features, vs 11.7 mg/L in those without; \( p = 0.01 \) (Figure 2).

### Disease activity and damage

NP involvement was associated with an increased number of ACR criteria fulfilled at last visit (\( p < 0.001 \)) (Table 3). The total pBILAG numerical disease activity score at first (\( p < 0.001 \)) visit, and SLICC damage scores at first (\( p = 0.02 \)) and last (\( p < 0.001 \)) visit were significantly higher in patients with NP involvement. In JSLE patients without NP involvement, renal involvement predominantly affected SLICC damage scores, followed by musculoskeletal, and skin manifestations (alopecia), while in patients with NP-SLE the presence of NP disease led to the increase in SLICC scores.

38% (20/52) of patients with “early” NP involvement had “severe” NP involvement, 56.4% (29/52) had “moderate” NP involvement, and the remaining 5.1% (3/52) of patients a “mild” NP involvement. At last visit, 6/52 (11.5%) patient with “early” NP involvement still had a “moderate” pBILAG defined NP involvement, while the majority of patients (46/52, 88.4%) had inactive neurological disease.

### Table 2. Comparison with other studies on juvenile-onset systemic lupus erythematosus (JSLE) with a neuropsychiatric (NP) involvement. SD, standard deviation; NS, nervous system.

| Country of study | Present study | YU et al. \(^{32}\) | Khajezadeh et al. \(^{33}\) | Zambrano et al. \(^{35}\) | Singh et al. \(^{34}\) |
|------------------|---------------|-----------------------|--------------------------|------------------------|---------------------|
| Cohort size      |               |                       |                          |                        |                     |
| Total JSLE patients, N | 428           | 185                   | 146                      | 90                     | 53                  |
| NP-SLE patients, N (%) | 107 (25%)    | 64 (34.6%)            | 41 (28%)                 | 30 (33.3%)             | 27 (50.9%)          |
| F:M ratio       | 5.4:1         | 5.9:1                 | 3:1                      | 5.4:1                  | 2.8:1               |
| Mean age (SD.)  | 12.2 (±3.1)   | 13.2 (±3)             | 10.2 (±3)                | 12.2                   | 9.9 (±3.2)          |
| Distribution of NP features (%) among NP-JSLE patients |               |                       |                          |                        |                     |
| Central NS      | 93            | 97                    | 99.3                     | 87                     | 94.4                |
| Peripheral NS   | 7             | 3                     | 0.7                      | 13                     | 5.6                 |
| Aseptic meningitis | 1.8          | 0                     | 0.7                      | NA                     | 3.7                 |
| Acute confusional state | 6.5      | 12.5                  | NA                       | 12.5                   | 7.5                 |
| Anxiety disorder | 23.3         | 6.3                   | NA                       | 23.3                   | 1.8                 |
| Cerebrovascular disease | 14.9    | 39                    | 5.3                      | 26                     | 11.3                |
| Cognitive dysfunction | 42         | 0                     | 11.6                     | NA                     | 17                  |
| Demyelinating syndrome | 1.8     | 3.1                   | NA                       | 1.8                    | NA                  |
| Headache        | 78.5          | 10.9                  | 13                       | 36                     | 39.6                |
| Movement disorders | 17.7       | 0                     | 3.4                      | 16                     | 5.6                 |
| Mood disorders  | 48.6          | 12.5                  | 5.4                      | NA                     | 9.4                 |
| Myelopathy      | 0.9           | 4.7                   | NA                       | NA                     | NA                  |
| Pychosis        | 9.3           | 21.9                  | 2.1                      | 13                     | 9.4                 |
| Seizures        | 19.6          | 84.4                  | 9.5                      | 50                     | 35.8                |
| Acute inflammatory demyelinating polyradiculoneuropathy | 1           | 0                     | NA                       | 6                      | NA                  |
| Autonomic disorders | 2.8       | 1.6                   | NA                       | NA                     | NA                  |
| Cranial neuropathy | 5.6        | 1.6                   | 0.7                      | NA                     | I                   |
| Mononeuropathy  | 8.4           | 3.1                   | NA                       | NA                     | NA                  |
| Myasthenia gravis | 0            | 0                     | NA                       | NA                     | NA                  |
| Plexopathy      | 0.9           | 0                     | NA                       | NA                     | NA                  |
| Polyneuropathy  | 1.8           | 4.7                   | N                        | NA                     | NA                  |
Among those 55 patients with a “late” NP involvement (namely, developed after their first visit), 2/55 (3.6%) had a “severe” NP pBILAG score at last visit, 7/55 (12.7%) had a “moderate” score, 5/55 (9%) a “mild” score, and 28/55 (51%) were inactive at last visit.

Five (1.1%) JSLE patients included in this study died during the observation period, two of whom experienced NP involvement; the small numbers limit statistical considerations.

**Discussion**

The current study is the largest to date examining the prevalence and associations with NP-SLE in a national JSLE population. Despite a conservative case definition for NP-SLE (in which isolated headaches, mood disorder or anxiety were not included if not accompanied by additional NP signs or symptoms), NP involvement was seen in 25% of UK JSLE Cohort Study patients within the first 5 years from diagnosis. NP involvement was generally shown to occur independently of single clinical and/or serologic SLE disease activity markers. The only laboratory parameters associated were low platelets and high CRP. NP involvement however was associated with additional SLE features (ACR classification criteria defined), and with higher global disease activity and damage scores.

NP involvement can be the result of antibody-mediated pathology, vasculitis, and/or increased permeability and dysfunction of the blood–brain/CSF barrier, resulting in the influx of neuropathic antibodies, cytokines, and lymphocytes promoting inflammation and damage. The situation is further complicated by chronic systemic inflammation,
impairment/damage to other organs, and/or treatment side-effects potentially contributing to NP manifestations (e.g. mood disorders and/or headaches). Though the pathophysiological causes are largely unknown, increased incidence, and severity of NP involvement in JSLE as compared to adult-onset SLE patients may be linked to a higher prevalence of rare “monogenic” disease causes, and overall increased genetic burden among JSLE patients. Furthermore, immunological, neuro-anatomical, and developmental differences between children and adults may play a role.

Depending on the study, patient cohorts included, and case definitions applied, NP manifestations have been reported in 14%–80% of adult-onset SLE patients, and in 22%–95% of JSLE patients. Stringent criteria were applied in the current study (as outlined above), excluding patients with singular potentially unspecific symptoms. Consequently, 25% of JSLE patients were classed as having NP involvement, with nearly half of NP-JSLE patients exhibiting NP involvement already at the time of their first hospital visit.

In a cohort of 185 Chinese JSLE patients, 22% of NP-JSLE patients had NP symptoms at diagnosis, and 32.8% within the first year. Among 146 Iranian JSLE patients, as many as 43.9% exhibited NP disease at the time of diagnosis, an additional 24.4% developed it during their first year. The higher incidences of NP involvement reported in these studies may relate to the case definitions used, in particular, not excluding patients with isolated headaches from the study population.

In agreement with other studies, we observed a female predominance (female: male ratio of 5.4:1), and a median age at diagnosis of 12.2 years in both entire cohort and the NP-JSLE sub-population. Similarly, NP-JSLE patients more frequently experienced CNS (as compared to PNS) involvement, which agrees with the published literature. However, the distribution of individual neurological symptoms differs between studies, with increased prevalence of headaches, cognitive impairment, mood disorders, and anxiety, and a lower frequency of seizures in the this study population. Notably, while ethnic minority groups were over-represented among JSLE patients as compared to national census data from the UK, sex, and racial composition did not differ between JSLE patients with vs patients without NP involvement. Of note, one of the particular strengths of this study is the multiethnic composition of the UK JSLE Cohort Study, as other studies were performed in relatively homogenous populations.

As reported previously by others, headaches were the most common NP symptom in the UK JSLE Cohort (78.5%), in accordance with adult SLE series reporting prevalence of headaches to range between 23% and 68%. The ACR case definition of NP syndromes mentions five types of headaches (migraine, tension headache, cluster headache, headache due to intracranial hypertension, and intractable nonspecific headache) based on the International Headache Society classification, without distinctions indicative for specific SLE etiology. All of these are reflected in the UK JSLE Cohort with similar distribution between the NP-SLE group and the remaining JSLE patient sub-cohort.

Psychiatric symptoms were the second most common group of NP manifestations in this cohort. On the basis of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), mood disorders encompass two main groups of conditions: depressive and related disorders, and bipolar, and related disorders. Usually, SLE is associated with depressive symptoms, while bipolar disorders are rare. In this study, almost 48% of NP-JSLE patients exhibited mood disorder. In 17.3% of the cases, symptoms were severe and classified as “major depression.” While mood disorders can generally occur in patients with chronic disease, previous studies have suggested that anxiety levels are significantly higher in adult-onset SLE patients when compared to healthy controls or RA patients ($p = 0.02$ and 0.01, respectively). Severe anxiety was present in 23.3% of NP-SLE patients in the current study, while an acute confusional state was observed in a small percentage of children (6.5% of NP-SLE patients).

Psychosis was observed in 10 patients (9.3%), six with an acute manifestation and four with a chronic course. Psychosis is a rarely reported feature, mainly during the early phases of the disease course; it was present in 28/1826 (1.53%) of adult SLE patients, mostly occurring early after disease onset and associating with a negative impact on health status.

This and data from additional pediatric studies (Table 2) suggests markedly higher prevalence of psychosis in JSLE as compared to adult-onset SLE patients. Among environmental or social factors, differences between studies may be explained by ethnicity-related genetic variables that affects both the disease’s clinical course and outcomes in JSLE. Indeed, considering Asian JSLE populations, in the UK, East Asian patients are under-represented, while South Asian patients account for the majority of Asian JSLE patients.

Approximately 15% of the entire UK JSLE Cohort experienced cognitive impairment. The majority (69%) already exhibited this at first visit. Due to its variable presentation, and the difficulty verifying/quantifying cognitive impairment, the reported incidence of cognitive impairment in adult-onset SLE cohorts has been shown to vary widely (6–80%). Similar variability is also observed in JSLE (see Table 2) with neurocognitive impairment reported in up to 71% of US American JSLE patients and the University of New Mexico Lupus Cohort demonstrating cognitive disorder in 55% of JSLE cases. Again, differences in ethnicity may in part account for some of the
variability between published cohorts. Cognitive dysfunction can also include a wide range of symptoms, affecting language, attention, reasoning, memory, executive skills, visual-spatial processing and psychomotor skills, accounting for some of these differences. The presence of potential confounders, such as socioeconomic factors, infections, or drug side-effects (e.g. corticosteroids, hydroxychloroquine), the lack of standardized assessments, and limitations of available neuropsychological tests contribute to under-diagnosis and imprecise estimates of the prevalence, incidence, and severity of cognitive impairment. This is further complicated in childhood where a degree of developmental variability is physiological. Lastly, overlapping mood disturbances can mask or complicate cognitive disorders. Indeed, 50% of the UK JSLE Cohort patients experiencing cognitive dysfunction had a concurrent mood disorder, such as depression or psychosis.

In this study, 19.6% of NP-SLE patients experienced seizures, mostly during the early phase of the disease (17/21). In two patients (1.8%), a diagnosis of epilepsy was made. Compared to other published reports, this proportion is relatively low (see Table 2). In adult-onset SLE cohorts, epilepsy, and/or seizures occur in up to 11.5% of patients. Younger patient age and high disease activity may be independent predictors of seizures. In a Chinese cohort of juvenile NP-SLE patients, seizures were one of the most frequent NP-JSLE-related symptoms, observed in 84% of NP-JSLE patients. Of note, half of patients enrolled in the UK JSLE Cohort Study who developed seizures were Caucasian and half South Asian. As 53.2% of NP-SLE patients were of White Caucasian, and 24.4% of South Asian descent, this suggests an over-representation of South Asian patients in this sub-cohort. Seizures are associated with the presence of anti-phospholipid (aPL) and anti-β2 glycoprotein (GPI) antibodies in adult-onset SLE patients, with GPI antibodies linked to intractable headaches and ischemic stroke. Incomplete data on the presence of aPL antibodies and a lack of centralized aPL testing precludes meaningful assessment of the role of such antibodies in the current cohort.

Cerebrovascular disease affected 14.9% of NP-JSLE patients in this study, in 87% at disease onset. Ischemic stroke accounted for half of cerebrovascular events, in contrast to 5–39% in reported cases. However, some studies did not distinguish stroke within this category by combining CNS vasculitis as well. In patients with adult-onset SLE the risk of ischemic stroke is two-fold higher when compared to the general population, and younger subjects (<50 years of age) in an early and active phase of the disease are more prone to develop this complication. Socioeconomic and racial variations may influence the risk for CNS infarctions, with Black and Hispanic patients being at a particular high risk. In this study, cerebrovascular involvement (including vasculitis and stroke) in 50% affected white Caucasian and in 50% South Asian patients, thus over-representing South Asians (24.2% of NP-SLE sub-cohort). Lastly, aPL antibody positivity increases the stroke risk at any time during the disease course, independent of the inflammatory activity. As mentioned above, aPL were not determined in all cases here which makes an assessment impossible.

Movement disorders, including chorea, cerebellar ataxia, and other types of abnormal movements, were present in 17.7% of the presented NP-JSLE cohort. This is comparable to the reported frequency in a Columbian juvenile NP-SLE population, while movement disorders were less common in Indian, Iranian, and in the Chinese cohort in which no patient showed this complication. While most patients experienced CNS symptoms related to NP-SLE, 7% developed peripheral neuropathy. Within this group, mononeuropathy (41%), cranial nerve involvement (27%), polyneuropathy (9%), and autonomic neuropathy (13.6%) were most common. In the adult literature, peripheral involvement has been reported in 2.2–32%, and appears to correlate with disease activity. Limited reports in the pediatric age group suggest PNS involvement in 0.7–13%. The small number of patients with PNS involvement in the current cohort prevents any meaningful analysis.

Comparing JSLE patients with NP involvement to the rest of the UK JSLE Cohort, no differences were recorded in autoantibody patterns and immune cell counts. Low platelet counts (<100 × 10⁹/L) were more common in NP-SLE patients at first visit. Furthermore, CRP was higher in NP-SLE patients. Of note, associations between CRP elevation and disease activity in SLE have been established. However, in suspected cases of NP-SLE it is crucial that infections (in particular meningitis and encephalitis) are considered and excluded. NP-SLE patients also exhibit a higher total numerical pBILAG disease activity scores at first visit, and an overall higher number of ACR criteria present at last visit, with higher SLICC damage index scores at first and last visit. Lastly, among patients with NP-JSLE, those with neurologic involvement early in the disease course exhibited higher disease activity (pBILAG) when compared to those with a later onset of NP symptoms. Taken together, laboratory, and clinical data from this study suggest a relationship between high disease activity and the development of NP involvement. This, though numbers are too low to draw definite conclusions, is underpinned by increased mortality in NP-SLE patients from the UK JSLE Cohort; five deaths were recorded in the entire UK JSLE cohort (mortality overall: 1.1%), two in the NP-JSLE subgroup (mortality: non–NP-SLE: 0.7% vs NP-SLE 1.86%).

We acknowledge certain strengths and limitations of this study. This is the one of the largest studies to date offering a detailed description of the different features related to NP-SLE. In contrast to other recent large NP-JSLE case series,
which included Middle Eastern, South Asian, and East Asian patients, this multiethnic cohort also includes Black African/Caribbean and White Caucasian patients. Limitations include incomplete datasets in relation to autoantibody status (in particular the presence of aPL was not always reported), and the possible underestimation of mild NP signs or symptoms. Furthermore, exclusion of patients with singular headaches, mood disorder, or anxiety may have resulted in an underestimation of NP-JSLE prevalence and incidence, but limits false inclusion of individuals, for example, experiencing drug-related symptoms (e.g. dysphoria in the context of corticosteroids).

**Conclusions**

NP involvement is common in this national cohort of JSLE patients (25%), and in half of all cases already present at diagnosis. Clinical features are variable and can be nonspecific, which makes diagnosis a challenge and holds the potential of under-recognition and the development of complications. To avoid diagnostic and therapeutic delay, NP involvement should be considered in all JSLE patients, including testing for cognitive impairment. Of note, NP-JSLE is associated with increased disease activity (pBLA, and CRP elevation), and damage (SLICC-SDI index) that may contribute to increased mortality. Future studies are warranted, focusing upon the impact of NP involvement on treatment response, permanent damage, and quality of life. International collaboration is needed to dissect disease aspects related to ethnic, genetic, and socioeconomic factors.

**Acknowledgments**

The authors would like to acknowledge all patients and their families for participating in this UK JSLE Cohort Study. Specifically, the authors are grateful to all the support given by the entire multi-disciplinary team within each of the pediatric centers who are part of the UK JSLE Study Group (https://www.liverpool.ac.uk/translational-medicine/research/ukjsle/jsle/). The study was supported by the National Institute of Health Research (NIHR) Clinical Research Network (CRN): Children’s National Specialty Group and CRN Research Nurses and staff in both UK centers, the NIHR Alder Hey Clinical Research Facility for Experimental Medicine, the UK’s “Experimental Arthritis Treatment Center for Children (EATC4Children)”, and all those who have supported the work of the UK JSLE Study Group to date. Special recognition also goes to Carla Roberts for co-ordination of the UK JSLE Cohort Study. The authors also thank Dr Cecilia Chighizola (University of Milano, Italy) for support with statistical analysis.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The UK JSLE Cohort Study and Repository is supported by LUPUS UK and Versus Arthritis UK, and the University of Liverpool, and the EATC4Children by Versus Arthritis UK, University of Liverpool and Alder Hey Children’s Foundation Trust.

**ORCID iDs**

Eve MD Smith  https://orcid.org/0000-0002-8371-7597
Coziana Ciurtin  https://orcid.org/0000-0002-8911-4113
Christian M Hedrich  https://orcid.org/0000-0002-1295-6179

**References**

1. Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol 2019; 209: 108274.
2. Massias JS, Smith EM, Al-Abadi E, et al. Clinical and laboratory phenotypes in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus 2021; 30(4): 597–607.
3. Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology 2017; 56: 1945–1961.
4. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2016; 75: 136–141.
5. Cimaz R. Phenotype and prognosis of juvenile systemic lupus erythematosus. Nat Rev Rheumatol 2016; 12: 382–383.
6. Massias JS, Smith EMD, Al-Abadi E, et al. Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across ethnicities in the UK. Lupus 2020; 29: 474–481.
7. Muscal E and Brey RL Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 2010; 28: 61–73.
8. The American college of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.
9. Brunner HI, Gladman DD, Ibañez D, et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 2008; 58: 556–562.
10. Tucker L, Uribe A, Fernández M, et al. Adolescnt onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008; 17: 314–322.
11. Hedrich CM, Zappe H, Straub S, et al. Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options. Clin Rheumatol 2011; 30: 275–283.
12. Soybilgic A. Neuropsychiatric systemic lupus erythematosus in children. *Pediatr Ann* 2015; 44: e153–8.

13. Mackay M, Tang CC and Vo A. Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus. *Curr Opin Neurol* 2020; 33: 353–361.

14. Torrente-Segarra V, Salman Monte TC, Rúa-Figueroa I, et al. Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish society of rheumatology lupus registry (RELESSER). *Clin Exp Rheumatol* 2017; 35: 1047–1055.

15. Carreño L, López-Longo FJ, Monteagudo I, et al. Immuno- and neurological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. *Lupus* 1999; 8: 287–292.

16. Hoffman I, Lauwerys BR, De Keyser F, et al. Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. *Ann Rheum Dis* 2009; 68: 412–415.

17. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40: 1725.

18. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. *Arthritis Rheum* 2012; 64: 2356–2365.

19. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996; 39: 363–369.

20. Gelb S, Stock AD, Anzi S, et al. Mechanisms of neuropsychiatric lupus: the relative roles of the blood-cerebrospinal fluid barrier versus blood-brain barrier. *J Autoimmun* 2018; 91: 34–44.

21. Tarr T, Dérfalvi B, Győri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. *Lupus* 2015; 24: 796–803.

22. Belot A, Rice GJ, Omarjee SO, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. *Lancet Rheumatol* 2020; 2: e99–e109.

23. Tsokos GC. Systemic lupus erythematosus. *New Engl J Med* 2011; 365: 2110–2121.

24. Webb R, Kelly JA, Somers EC, et al. Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. *Ann Rheum Dis* 2011; 70: 151–156.

25. Sibbitt WL, Brandt JR, Johnson CR, et al. The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. *J Rheumatol* 2002; 29: 1536–1542.

26. Ainaia H, Loukkola J, Peltola J, et al. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. *Neurology* 2001; 57: 496–500.

27. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. *Neurology* 2002; 58: 1214–1220.

28. Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study. *Arthritis Rheumatol* 2007; 56: 265–273.

29. Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. *J Rheumatol* 2006; 33: 1873–1877.

30. Benseler SM and Silverman ED. Review: Neuropsychiatric involvement in pediatric systemic lupus erythematosus. *Lupus* 2007; 16: 564–571.

31. Hiraki LT, Benseler SM, Tyrrell PN, et al. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. *J Pediatr* 2008; 152: 550–556.

32. Yu H-H, Lee J-H, Wang L-C, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus: a 20-year study. *Lupus* 2006; 15: 651–657.

33. Khajezadeh M-A, Zamani G, Moazzami B, et al. Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus. *Neurol Res Int* 2018; 2018: 1–7.

34. Singh S, Gupta MK, Ahiulwalia J, et al. Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India. *Rheumatol Int* 2009; 29: 1455–1461.

35. Zuniga Zambrano YC, Guevara Ramos JD, Penagos Vargas NE, et al. Risk factors for neuropsychiatric manifestations in children with systemic lupus erythematosus: case-control study. *Pediatr Neurol* 2014; 51: 403–409.

36. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. *Cephalalgia* 2004; 24(Suppl 1): 9–160.

37. Hanly JG, Su L, Urowitz MB, et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. *Arthritis Rheumatol* 2015; 67: 1837–1847.

38. Figueiredo-Braga M, Cornaby C, Cortez A, et al. Depression and anxiety in systemic lupus erythematosus. *Medicine* 2018; 97: e11376.

39. Hanly JG, Li Q, Su L, et al. Psychosis in systemic lupus erythematosus: results from an international inception cohort study. *Arthritis Rheumatol* 2019; 71: 281–289.

40. Schwartz N, Stock AD and Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. *Nat Rev Rheumatol* 2019; 15: 137–152.

41. Muscal E, Bloom D, Hunter J, et al. Neurocognitive deficits and neuroimaging abnormalities are prevalent in children with lupus: clinical and research experiences at a US pediatric institution. *Lupus* 2010; 19: 268–279.

42. Hopia L, Andersson ., Svenungsson E, et al. Epilepsy in systemic lupus erythematosus: prevalence and risk factors. *Eur J Neurol* 2020; 27: 297–307.

43. Andrade RM, Alarcon GS, Gonzalez LA, et al. Seizures in patients with systemic lupus erythematosus: data from...
44. Rosati A, Guerrini R and Cimaz R. Lupus, antiphospholipid syndrome and epilepsy: an update. *Lupus* 2017; 26: 3–5.

45. Hawro T, Bogucki A, Krupińska-Kun M, et al. Intractable headaches, ischemic stroke, and seizures are linked to the presence of Anti-β2GPI antibodies in patients with systemic lupus erythematosus. *PLoS One* 2015; 10: e0119911.

46. Holmqvist M, Simard JF, Asplund K, et al. Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. *RMD Open* 2015; 1: e000168.

47. Nikolopoulos D, Fanouriakis A and Boumpas D. Cerebrovascular events in systemic lupus erythematosus: diagnosis and management. *Mediterr J Rheumatol* 2019; 30: 7–15.

48. Barbhaiya M, Feldman CH, Guan H, et al. Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. *Semin Arthritis Rheum* 2019; 48: 840–846.

49. Xianbin W, Mingyu W, Dong X, et al. Peripheral neuropathies due to systemic lupus erythematosus in China. *Medicine* 2015; 94: e625.

50. Almeida RT, Campos LMdeA, Aikawa NE, et al. Peripheral polineuropathy in patients with juvenile systemic lupus erythematosus. *Bras J Rheumatol* 2009; 49: 362–374.

51. Wang J, Niu R, Jiang L, et al. The diagnostic values of C-reactive protein and procalcitonin in identifying systemic lupus erythematosus infection and disease activity. *Medicine* 2019; 98: e16798.